Key Points
- Director George Morrow sold 15,000 shares at an average of $143.37 for a total of $2,150,550, leaving him with 7,068 shares—a 67.97% reduction in his ownership.
- Neurocrine posted a strong Q3 with EPS of $2.17 vs. $1.58 expected and revenue of $794.9M (up 27.8% YoY), and multiple analysts raised price targets, yielding a MarketBeat consensus of "Moderate Buy" with a $170.53 target.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director George Morrow sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the sale, the director directly owned 7,068 shares of the company's stock, valued at approximately $1,013,339.16. This represents a 67.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Neurocrine Biosciences Stock Performance
NBIX opened at $151.58 on Thursday. The stock's fifty day moving average is $142.62 and its 200-day moving average is $134.47. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.67. The company has a market capitalization of $15.11 billion, a PE ratio of 36.26, a P/E/G ratio of 0.94 and a beta of 0.22.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, topping the consensus estimate of $1.58 by $0.59. The firm had revenue of $794.90 million for the quarter, compared to analysts' expectations of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. Neurocrine Biosciences's revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.81 earnings per share. On average, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.
Hedge Funds Weigh In On Neurocrine Biosciences
Several institutional investors and hedge funds have recently bought and sold shares of the business. Dodge & Cox lifted its position in shares of Neurocrine Biosciences by 0.6% in the second quarter. Dodge & Cox now owns 5,566,814 shares of the company's stock worth $699,693,000 after purchasing an additional 32,190 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Neurocrine Biosciences by 11.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company's stock valued at $664,019,000 after buying an additional 468,405 shares during the period. AQR Capital Management LLC lifted its position in Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company's stock worth $388,435,000 after buying an additional 1,263,633 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Neurocrine Biosciences by 44.0% during the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock valued at $232,037,000 after acquiring an additional 640,556 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Neurocrine Biosciences by 3.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company's stock worth $170,281,000 after acquiring an additional 49,088 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.
Analyst Ratings Changes
Several research firms have issued reports on NBIX. Piper Sandler lifted their price target on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 29th. Weiss Ratings restated a "hold (c+)" rating on shares of Neurocrine Biosciences in a report on Wednesday, October 8th. UBS Group upped their target price on Neurocrine Biosciences from $188.00 to $195.00 and gave the company a "buy" rating in a report on Thursday, October 9th. Guggenheim lifted their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Citigroup upped their price objective on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the company a "buy" rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.53.
View Our Latest Stock Analysis on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
